themarker Posted - 1 hour ago

Cathie Wood and Ark Invest's trade activity from 2024/04/18 $STNE $TWLO $VRTX

kamenrider888 Posted - 5 hours ago

$VRTX not worth more than $280..still even under $400 now is still overvalued like Purdue was as they try to sweep all the patient serious bad side effects under their bankers and analysts rugs...reminds me of early days MBOT. Vertex products are being very overrated.

ElijahJobs Posted - 9 hours ago

$VRTX Accumulating shares whenever it dips below 400. Very nice bargains, indeed. Next year when non-addictive pain killer gets approved, will see this in the 600’s. JMO

BosFreedom Posted - 12 hours ago

$VRTX will they have any crispr sales for Q1?

Real_Men_of_Genius Posted - 15 hours ago

$VRTX is one of the best large biotechs, perhaps the top company, if their pain med can get approved and not end up like $NKTR

cambob Posted - 16 hours ago

$VRTX Historically high ROIC and significant increase in invested capital this past year. Pharma is a slow industry so the returns on the newly invested capital probably won’t be realized immediately but I have faith that this is a top quality healthcare company and capital allocator.

TradingUK Posted - 16 hours ago

$DFLI $INDO $HUSA $VRTX $HNRA ENERGY BACK ON THE RISE = BUY 🚨

DonCorleone77 Posted - 18 hours ago

$VRTX Vertex Pharmaceuticals announces advancements in suzetrigine pain program Vertex Pharmaceuticals announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades. Suzetrigine is an oral selective NaV1.8 pain signal inhibitor. Following the positive Phase 3 results in acute pain announced in January, the FDA has granted a rolling New Drug Application (NDA) submission for suzetrigine in moderate-to-severe acute pain. Vertex has started the rolling submission process and is on track to complete the submission in the second quarter of 2024. Suzetrigine was previously granted FDA Fast Track and Breakthrough Therapy designations in moderate-to-severe acute pain. In neuropathic pain, Vertex released positive results from its Phase 2 study in December 2023 and recently completed a successful end-of-phase 2 meeting with the FDA. Vertex is now preparing to initiate a Phase 3 pivotal program of suzetrigine in patients with DPN in 2H 2024. In addition, the FDA recently granted suzetrigine Breakthrough Therapy designation for the treatment of pain associated with DPN. The Phase 3 program will include two identical 12-week randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of suzetrigine in patients with DPN. The primary endpoint for both studies will be the change from baseline in weekly average of daily pain intensity on the numeric pain rating scale, or NPRS, assessed at Week 12 compared to placebo. Both studies will also include a key secondary endpoint of change from baseline in the weekly average of daily pain intensity on the NPRS at Week 12 compared to pregabalin. Approximately 1,100 patients are expected to enroll in each Phase 3 study. After completing participation in the randomized controlled studies, patients may roll over into an open-label study to evaluate the long-term safety and effectiveness of suzetrigine in DPN. Additionally, Vertex continues to enroll its Phase 2 study of suzetrigine in patients with lumbosacral radiculopathy, or LSR, which is pain caused by impairment or injury to nerve roots in the area of the lumbar spine. The company is on track to complete enrollment in the Phase 2 LSR study by the end of the year.

kagrawala Posted - 18 hours ago

$VRTX nice news on VX-548 today. https://news.vrtx.com/news-releases/news-release-details/vertex-announces-advancements-suzetrigine-vx-548-acute-and

Stock_Titan Posted - 19 hours ago

$VRTX Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain https://www.stocktitan.net/news/VRTX/vertex-announces-advancements-of-suzetrigine-vx-548-in-acute-and-bl8k4guie2x1.html

Thestocktraderhubzee Posted - 19 hours ago

$VRTX Guggenheim Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $450

Rubiks_KubeMD Posted - 1 day ago

$VRTX when this breaks north of about 425 on the way back up punch your tickets... No idea exactly when but before eoy an epic run is in the cards.

Rubiks_KubeMD Posted - 1 day ago

$VRTX wow... It's going to head even deeper into oversold territory here 👀 Long term am super bullish but in the short term yikes... 😬

stubbybrown Posted - 1 day ago

$VRTX very close to oversold territory. Will consider adding if the 24hr RSI drops below 30 down to 25.

kamenrider888 Posted - 2 days ago

$VRTX still too overvalued

JFDI Posted - 3 days ago

$VRTX back thru 400

kamenrider888 Posted - 4 days ago

$VRTX as predicted..below $400 already lol

cuttail07 Posted - 5 days ago

$VRTX Regarding the Alpine acquisition: Reshma is a board certified nephrologist. Her excitement about the prospects for Povetacicept in various nephropathies (most notably IgAN at this time) was palpable on the conference call. I trust her on this one. But I’m putting this on the back burner for the next 18-24 months. What I really want to hear about is a strong focus on Vanza triple and VX-548 approvals and launches. These will be the main revenue adds to the company over the next 2 years.

Timefortendies77 Posted - 5 days ago

$VRTX Once we get a PDUFA data for the pain drug, and that date gets closer the party will begin again--until then not worth the investment.

cuttail07 Posted - 6 days ago

$VRTX 15% increase in my position today.

GreenGoblin_ Posted - 6 days ago

@BioRunner9 wrong stock $VRTX

russellkbrett Posted - 6 days ago

$EDIT What a walk down! Market cap getting closer to the $427M they have just in cash & cash equivalents. 6-straight weeks down -46% off post Q4 ER high where they beat estimates for the 3rd consecutive quarter narrowing EPS loss to -$0.23 from -$0.55 prev and blew out the revenue estimates ($60M vs $3.70M est) due to $VRTX licensing deal. Short interest has grown to more than 20% of float now (over 16M shares). Last time SI was this high, it preceded a big multiweek rally. We'll see. Holding on here..

blueb22 Posted - 6 days ago

$BLUE $vrtx $crsp - CMS CGT Access model (SCD Gene therapies at this time) home page (Looks like they are continuing to update this with milestone reached and many links and all that -- good to bookmark this page for easy reference) for those invested in SCD Gene therapies (Lyfgenia and Casgevy) https://www.cms.gov/priorities/innovation/innovation-models/cgt

UncleStock Posted - 1 week ago

$FANG $VRTX $MNST $META suggested for $NDX US NASDAQ 100 - value screen: https://zpr.io/tk2Y7

SemisbullWatermelon Posted - 1 week ago

$VRTX any body has any idea why VRTX down so much recently?

svertical1 Posted - 1 week ago

$CRSP $VRTX No small benefit for VRTX success as well.

svertical1 Posted - 1 week ago

$CRSP $VRTX Important for VRTX results as well!

DoctrBenway Posted - 1 week ago

$BLUE $CRSP $VRTX https://endpts.com/cms-to-increase-reimbursement-for-new-sickle-cell-gene-therapies/

ProKnifeCatcher87 Posted - 1 week ago

$REGN politicians are crooked Shame Shame Shame on them This is a life saving game changing company Thankyou for the dip !!! Added $235k to 401 today $VRTX $AMGN

theflynews Posted - 1 week ago

Analyst thinks this drugmaker could be next after Alpine's $4.9B acquisition - $VRTX - https://thefly.com/permalinks/entry.php/VRTXid389582